All News

pregnant woman

Add-on certolizumab in pregnant women with APS

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Women with antiphospholipid syndrome and lupus anti-coagulant are at high risk of developing adverse pregnancy outcomes (APO). Usual care includes low molecular weight heparin (LMWH) and low dose aspirin (LDA). Despite these therapies, APO have been reported up to 40%.

Read Article
nurse,appointment,vitals

Nurse-Led Treat-to-Target Clinics

EurekAlert!

New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.

Read Article
steroids.prednisone.pills_.jpg

How to properly use steroids in early RA

Janet Pope, MD, MPH, FRCPC

Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. We do know that it is not easy to get a significant minority of RA patients off of prednisone.

Read Article
question mark

Methotrexate and Leflunomide combination in RA/PsA: Is it safe?

Aurelie Najm, MD, PhD

I asked the EULAR twitter sphere how they feel about combination of methotrexate (MTX) and leflunomide (LEF). The opinions are differing so far, with 50% reporting prescribing this combination often while 50% are worried of side effects. Several abstracts presented this year are providing further data to help us make up our minds in RA and PsA.

Read Article
lupus,nephritis,GN

2025 update of EULAR recommendations on lupus nephritis

Md Yuzaiful Md Yusof, MRCP(UK), PhD

At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented a summary of the updated EULAR recommendations on the management of lupus nephritis (LN). The most significant change in the treatment paradigm of LN is that the historic standard of care (SOC) (i.e.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy outcomes in autoinflammatory disease

EurekAlert!

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health.

Read Article
Safety of Recombinant Zoster Vaccine in Rheumatic Patients New work presented at EULAR focuses on the RZV, which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory https://t.co/NS3h9CdGIU
Dr. John Cush RheumNow ( View Tweet)
Cancer risk in rheumatoid arthritis: anything new? There is still a question I have a hard time answering with certainty when people living with rheumatoid arthritis ask me: Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many https://t.co/6rbZg5Fr2k
Dr. John Cush RheumNow ( View Tweet)
Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data Dr. Mrinalini Dey reports on abstract OP0070, "Trends in Incidence and Predictors of Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study", https://t.co/JykR4Mxb9L
Dr. John Cush RheumNow ( View Tweet)
The Impact of Biologics on Methotrexate Adherence Dr. Aurelie Najm reports on abstract POS0563, 'Methotrexate biochemical adherence significantly reduces in new starters of biologic/targeted DMARDs: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study https://t.co/t7DEsJW35v
Dr. John Cush RheumNow ( View Tweet)
Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush RheumNow ( View Tweet)
Sometimes you hear: “PMR dose steroids don’t really matter” Errrrr… (You wouldn’t accept this steroid exposure in any other disease. Never) #EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj

Links:

David Liew drdavidliew ( View Tweet)
Management of SLE: -Treat early to prevent organ damage -Taper GC to <5mg/d in the first 6m when feasible -New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy. #EULAR2025 @RheumNow https://t.co/UKK8sTYJD2

Links:

Adela Castro AdelaCastro222 ( View Tweet)
-Difficult to treat RA is a heterogeneous concept -Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression. -Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options). -The https://t.co/ZCZcX9FRfb

Links:

Adela Castro AdelaCastro222 ( View Tweet)
#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

#Enpatoran a #TLRi in Phase2 #SLE #RCT -previous data + small #cutaneous #lupus study various doses &PBO approx 25/group Interesting data - seems to ⬇️#IFN + endpoints 👀 for more to come! Safe so far #EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX

Links:

Janet Pope Janetbirdope ( View Tweet)
FMF #Recommendations #Colchicine can be fatal 🔺️Beware of drug interactions 🔺️Mostly statins in adults 🔺️Macrolides in children #EULAR2025 @RheumNow https://t.co/SYGLpAJXFu

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×